Stay updated on A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe page adds new navigation sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', and standardizes the Intervention/Treatment heading. It also introduces metadata labels 'Last verified' and 'Last known status was:' plus a 'Revision: v3.6.0' indicator to reflect updated documentation structure.SummaryDifference2%

- Check16 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5, indicating a minor behind-the-scenes update to the study record. This does not alter the study details or eligibility criteria.SummaryDifference0.1%

- Check37 days agoChange DetectedVirogen Biotechnology Inc. was added as sponsor and Angimmune LLC was removed as a collaborator. The study record revision was updated from v3.5.3 to v3.5.4.SummaryDifference0.3%

- Check59 days agoChange DetectedThe page’s site revision indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check95 days agoChange Detected- Revision: v3.5.0 implemented. - Previous revision: v3.4.3 removed. - No visible changes to study details or page content.SummaryDifference0.1%

Stay in the know with updates to A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the A-dmDT390-bisFv & Pembrolizumab in Melanoma Clinical Trial page.